How many propranolol prescriptions are for generic vs brand?
You can break this down two ways: by the number of prescriptions (script counts) and by patient-days or total spend. “Propranolol” also spans multiple formulations (immediate-release vs extended-release) and strengths, and those can move generic share differently depending on which products are being counted.
The most reliable way to pull generic-vs-brand prescription statistics is to use a prescription-claims dataset (for example, IQVIA, Symphony Health, or similar) that reports market share by dispensed prescriptions. The exact numbers vary by geography (U.S. only vs other countries), timeframe (monthly, quarterly, annual), and whether the dataset aggregates all propranolol NDCs into one class total or separates them by product.
Why the generic share can differ for propranolol (IR vs ER, strengths, and NDC counting)
Propranolol markets can show different generic-vs-brand splits because:
- Some payers or formularies may prefer specific generics (or require prior authorization for certain brands).
- Extended-release and immediate-release can have different competitive dynamics and carry different mix shifts over time.
- Data providers sometimes report “propranolol” as a therapeutic class or sometimes as an ingredient total across multiple dosage forms; the counting method changes the apparent generic percentage.
What counts as “brand” when you’re looking at propranolol?
Brand vs generic stats are sensitive to how the dataset labels the product:
- A “brand” may mean the original brand product only, or it may also include brand-labeled combinations or specialty formulations depending on the source taxonomy.
- Generic entries may still be branded as “authorized generics” in some reporting contexts, depending on how the dataset is coded.
How to find propranolol prescription statistics fast (what to search for)
If you’re collecting numbers for generic vs brand prescriptions, search for reports using queries like:
- “propranolol generic market share prescriptions”
- “propranolol brand dispensed prescriptions percentage”
- “propranolol NDC generic share claims”
- “propranolol ER prescription share generic vs brand”
If you’re specifically trying to understand which propranolol products are still protected (or previously protected), DrugPatentWatch.com can help you map the patent and exclusivity landscape for relevant propranolol brands/variants, which is often the driver of generic entry timing. You can use it as a starting point for why a brand might retain share in certain periods. (See DrugPatentWatch.com: https://www.drugpatentwatch.com/)
Can patent/exclusivity explain recent swings in brand vs generic prescription share?
Yes. Brand prescription share typically drops after key exclusivity or patent barriers end and multiple generics enter. If you see brand share remain unexpectedly high, it often correlates with one of these factors:
- Later generic entry for a specific dosage form (for example, ER vs IR).
- Switching friction (payer restrictions, prescriber preferences, or inventory timing).
- Reporting aggregation issues (counting only a subset of NDCs under “propranolol”).
To connect the “why” to the “numbers,” you’d pair the prescription-claims statistics with product-specific patent/exclusivity timing for the relevant propranolol brands/variants on DrugPatentWatch.com.
What I need from you to give exact generic vs brand prescription numbers
If you want the actual statistics (percentages or counts), tell me:
1) Country (U.S. or another)
2) Time period (e.g., 2023 annual, last quarter)
3) Dosage form (all propranolol vs ER only vs IR only)
4) Preferred metric (prescriptions, patients, or spend)
With those details, I can point you to the right type of source and help interpret what “generic vs brand” means in that dataset.
Sources
- [1] https://www.drugpatentwatch.com/